Given that the patient had demonstrated the development of a clinically aggressive FL with early relapse that occurred prior to the onset of the PML, we believe that the recurrence of his lymphoma was unlikely associated with prolonged IL-2 therapy. Here, IL2 is linked to lymphoma.